Glucose homeostasis depends on the coordinated secretion of
glucagon,
insulin, and
Glucagon-like peptide (GLP)-1 by pancreas and intestine.
Obesity, which is associated with an increased risk of developing
insulin resistance and
type 2 diabetes, affects the function of these organs. Here, we investigate the functional and molecular adaptations of
proglucagon-producing cells in obese mice to better define their involvement in
type 2 diabetes development. We used GLU-Venus transgenic male mice specifically expressing Venus
fluorochrome in
proglucagon-producing cells. Mice were subjected to 16 weeks of
low-fat diet or high-fat diet (HFD) and then subdivided by measuring
glycated hemoglobin (HbA1c) in 3 groups:
low-fat diet mice and I-HFD (
glucose-intolerant) mice with similar HbA1c and H-HFD (hyperglycemic) mice, which exhibited higher HbA1c. At 16 weeks, both HFD groups exhibited similar
weight gain,
hyperinsulinemia, and
insulin resistance. However, I-HFD mice exhibited better
glucose tolerance compared with H-HFD mice. I-HFD mice displayed functional and molecular adaptations of enteroendocrine L-cells resulting in increased intestinal
GLP-1 biosynthesis and release as well as maintained pancreatic α- and β-cell functions. By contrast, H-HFD mice exhibited dysfunctional L, α- and β-cells with increased β- and L-cell numbers. Administration of the GLP-1R antagonist Exendin9-39 in I-HFD mice led to
hyperglycemia and alterations of
glucagon secretion without changes in insulin secretion. Our results highlight the cross-talk between islet and intestine endocrine cells and indicate that a compensatory adaptation of L-cell function in
obesity plays an important role in preserving
glucose homeostasis through the control of pancreatic α-cell functions.